Taiwan Bio Therapeutics (ROCO:6892) Total Inventories: NT$31.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6892 Taiwan Bio Therapeutics Inc ROCO:6892
22 GF Score
Price NT$26.90
GF Value NT$14.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Taiwan Bio Therapeutics Total Inventories?

Taiwan Bio Therapeutics ROCO:6892 +0.94% 22 Total Inventories is NT$31.1 Mil as of Dec. 2025. GuruFocus rates ROCO:6892 with a GF Score™ of 22/100 and a GF Value™ of NT$14.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Taiwan Bio Therapeutics's total inventories for the quarter that ended in Dec. 2025 was NT$31.1 Mil. Taiwan Bio Therapeutics's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was NT$34.2 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Taiwan Bio Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was NT$-3.70.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Taiwan Bio Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Taiwan Bio Therapeutics  (ROCO:6892) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Taiwan Bio Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(290.395+0.75 * 6.647+0.5 * 31.084-625.12
-0-0)/84.899
=-3.70

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Taiwan Bio Therapeutics's Days Inventory for the three months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=34.2225/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Taiwan Bio Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=0 / 34.2225
=0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Taiwan Bio Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=34.2225 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Taiwan Bio Therapeutics Total Inventories Related Terms

Taiwan Bio Therapeutics Total Inventories Historical Data

* Premium members only.

The historical data trend for Taiwan Bio Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics Total Inventories Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial 5.54 30.79 40.96 31.35 31.08

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.49 31.35 34.71 37.36 31.08
ROCO:6892
22GF Score
Taiwan Bio Therapeutics Inc ROCO:6892
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Bio Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of NT$31.1 Mil mean?
Taiwan Bio Therapeutics (ROCO:6892) has a Total Inventories of NT$31.1 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Taiwan Bio Therapeutics and its competitors.
Is Taiwan Bio Therapeutics' Total Inventories too high?
Taiwan Bio Therapeutics' current Total Inventories is NT$31.1 Mil. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' Total Inventories compare to VRTX and REGN?
Taiwan Bio Therapeutics' Total Inventories of NT$31.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Taiwan Bio Therapeutics and its competitors. Taiwan Bio Therapeutics's current Total Inventories is NT$31.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.66, compared to a current price of NT$26.90 — trading 83.5% above its estimated fair value. The current Total Inventories is NT$31.1 Mil. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current Total Inventories is NT$31.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued. The current stock price of NT$26.90 is trading 83.5% above its estimated GF Value™ of NT$14.66. GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.

Key valuation signals for ROCO:6892:

  • Total Inventories: NT$31.1 Mil
  • GF Value™: NT$14.66 vs. price of NT$26.90 (83.5% above fair value)
  • GF Score™: 22/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Bio Therapeutics Business Description

Address Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score

Get the complete analysis for ROCO:6892

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.90
Price
NT$14.66
GF Value